No sooner had cytokine therapies been labelled an area to watch in 2018 than Bristol-Myers Squibb paid a massive $1.85bn for rights to Nektar’s NKTR-214, and interest in IL-2 is not about to abate. Read MoreDownload Attachment
MassBio® members enjoy a wide range of benefits including networking and educational events, savings through our Purchasing Consortium, business development and entrepreneurial support programs, public policy and advocacy engagement and economic development support. MassBio membership is the best way for you and your organization to connect with the world’s leading life sciences supercluster.
Click here to begin the member application process.